Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 180

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

The anti-CD20 antibody rituximab reduces the Th17 cell response

van de Veerdonk, Frank L., Lauwerys, Bernard, Marijnissen, Renoud J., Timmermans, Kim, Di Padova, Franco, Koenders, Marije I., Gutierrez-Roelens, Ilse, Durez, Patrick, Netea, Mihai G., van der Meer, Jos W. M., van den Berg, Wim B., Joosten, Leo A. B. · 2011 · Arthritis & Rheumatism

Abstract

OBJECTIVE: Rituximab has been shown to be successful in the treatment of rheumatoid arthritis (RA), and this unexpected finding indicates that B cells have an important role in this disease. The present study was undertaken to investigate the mechanism of action of rituximab in RA. METHODS: Twelve patients with active RA were treated with rituximab. Disease activity was evaluated using the 28-joint Disease Activity Score. Synovial biopsy samples obtained at baseline and 12 weeks after treatment initiation were analyzed by microarray, quantitative polymerase chain reaction, and immunohistochemistry. Peripheral blood mononuclear cells (PBMCs) from healthy volunteers and from 4 patients with X-linked agammaglobulinemia were stimulated with the Th17-inducing stimulus Candida albicans, and the response in the presence and absence of rituximab was examined. RESULTS: In RA patients, rituximab reduced expression of retinoic acid-related orphan receptor γt and interleukin-22 (IL-22) and numbers of Th17-positive cells in synovial tissue, and this correlated with better clinical outcome. Rituximab did not affect tumor necrosis factor α (TNFα), Th1 cell, or Treg cell responses. Rituximab strongly reduced in vitro IL-17 and IL-22 production induced by C albicans. This effect was not observed in PBMCs from patients with X-linked agammaglobulinemia. CONCLUSION: Rituximab reduced the local Th17 response in RA patients, whereas it did not influence Th1 cell, Treg cell, or TNFα responses. The decreased Th17 response was associated with reduced inflammation and better clinical outcome. Moreover, inhibition of the Th17 response by rituximab was lost in the absence of B cells, providing evidence that the effects of rituximab are due to B cell depletion. These data demonstrate an unexpected role of B cells in the development of Th17 responses, which could possibly lead to B cell-based strategies for the treatment of Th17-related autoimmune diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.30314

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 180

Metadata

Authors
van de Veerdonk, F. L., Lauwerys, B., Marijnissen, R. J., Timmermans, K., Di Padova, F., Koenders, M. I., Gutierrez-Roelens, I., Durez, P., Netea, M. G., van der Meer, J. W. M., van den Berg, W. B., & Joosten, L. A. B.
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2011-05-31
Volume
63
Issue
6
Pages
1507-1516
ISSN
0004-3591 (ISSN-L)
OpenAlex
W2046188285
Cited by
180
References
6
FWCI
16.03
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The anti-CD20 antibody rituximab reduces the Th17 cell response. https://app.cochat.ai/papers/10.1002/art.30314
The paper
van de Veerdonk, F. L., Lauwerys, B., Marijnissen, R. J., Timmermans, K., Di Padova, F., Koenders, M. I., Gutierrez-Roelens, I., Durez, P., Netea, M. G., van der Meer, J. W. M., van den Berg, W. B., & Joosten, L. A. B. (2011). The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis & Rheumatism. https://doi.org/10.1002/art.30314

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.